 |
|
Modern Aspects of Cutaneous Neurogenic Inflammation
Martin Steinhoff, MD, PhD;
Sonja Ständer, MD;
Stephan Seeliger, MD;
John C. Ansel, MD;
Martin Schmelz, MD;
Thomas Luger, MD
Arch Dermatol. 2003;139:1479-1488.
ABSTRACT
| |
Recent findings have shed new light on the role of peripheral nerves in the skin and established a modern concept of cutaneous neurobiology. Closely related monodirectional and/or bidirectional pathways exist in which the central and peripheral nervous system, the endocrine and immune system, and almost all skin cells are involved. Information is emerging about the factors involved in these immunomodulatory mechanisms, which are defined as neuropeptides, neurotransmitters, neurotrophins, and neurohormones. The interaction between peripheral nerves and the immune system is mediated by different types of cutaneous nerve fibers that release neuromediators and activate specific receptors on target cells in the skin such as keratinocytes, mast cells, Langerhans cells, microvascular endothelial cells, fibroblasts, and infiltrating immune cells. These interactions influence a variety of physiologic and pathophysiologic functions including cellular development, growth, differentiation, immunity, vasoregulation, leukocyte recruitment, pruritus, and wound healing. A variety of mechanisms lead to the termination of cellular responses to released neuropeptides under physiologic circumstances. Herein, we highlight some of the recent advances of neurocutaneous biology and discuss the role of nerves in mediating cutaneous inflammation. Understanding the mechanisms and the factors controlling neuromediators and their receptors and degrading enzymes will lead to the identification of novel therapeutic targets for the treatment of cutaneous diseases.
ANATOMY OF THE PERIPHERAL NERVOUS SYSTEM
Afferent somatic nerves with fine unmyelinated (C-) or myelinated (A -) fibers derive from dorsal root ganglia and innervate the skin. Both types of fibers respond to a range of physiologic stimuli such as physical trauma (heat, cold, nociception, mechanical distension, and UV light) and even low-intensity mechanical stimulation. Furthermore, specialized nociceptor fibers can be activated by a wide range of chemicals, which indicates that not only physical but also chemical stimuli are capable of activating the cutaneous nervous system. Moreover, biological factors such as microbiological agents and proteases from plants (eg, papain and trypsins) are capable of stimulating sensory nerves in the skin. On stimulation, the nerves rapidly release active neuropeptides into the microenvironment. A short graphic summary of these factors appears at the end of this article. In addition to these exogenous trigger factors, endogenous stimuli such as like protons (pH changes), hormones, cytokines, proteinases, kinins, and probably other undefined mediators released by various cells involved in inflammatory processes induce activation of primary afferent neurons in many organs, including the skin (Figure 1).
|
|
|
|
Proteinase-activated receptor 2 (PAR-2) regulates inflammation by a neurogenic mechanism: (1) tryptase released from degranulated mast cells cleaves PAR-2 at the plasma membrane of sensory nerve endings to expose a tethered ligand domain that binds and activates the cleaved receptor; (2) activation of PAR-2 stimulates the release of calcitonin gene-related peptide (CGRP) and the tachykinins substance P (SP) and neurokinin A (NK-A) from sensory nerve endings; (3) CGRP interacts with the CGRP-1 receptor to induce arteriolar dilation and hyperanemia; (4) SP interacts with the neurokinin-1 (NK-1) receptor on endothelial cells of postcapillary venules to cause gap formation and plasma extravasation; the hyperanemia and plasma extravasation cause edema; (5) SP may stimulate degranulation of mast cells, providing a positive feedback; (6) tryptase degrades CGRP and terminates its effects; (7) CGRP inhibits SP degradation by neutral endopeptidase and also enhances SP release, thereby amplifying the effects; (8) mediators from mast cells and other inflammatory cells stimulate the release of vasoactive peptides from sensory nerves and also sensitize nerves; (9) in addition to peripheral stimulation of neurogenic inflammation, PAR-2 agonists induce central transmission of pain and pruritus. ATP indicates adenosine triphosphate.
|
|
|
Autonomic nerve fibers represent only a minority of cutaneous fibers that generate predominantly neurotransmitters such as acetylcholine and catecholamines. Autonomic nerves may also generate neuropeptides such as neuropeptide Y, calcitonin gene-related peptide (CGRP), atrial natriuretic peptide, and vasoactive intestinal peptide (VIP). Neuropeptides may be involved in the regulation of sweat gland function and vasoregulation.1-2 Recent findings suggest that classic autonomic neurotransmitters can also be generated by nonneuronal cells such as keratinocytes. In addition, muscarinic and nicotinergic acetylcholine receptor expression has been described on keratinocytes and Langerhans cells,3-4 which indicates a role of autonomic neuromediators in inflammation, epidermal function, and hair growth.5-8
LINKAGE OF PERIPHERAL NERVES WITH CUTANEOUS INFLAMMATION
A century ago, cutaneous vasodilatation was achieved after stimulation of cut dorsal nerve roots. Later, the identification and characterization of polymodal and chemosensitive small nerve fibers (C- and A-nociceptors) explained how nerves may participate in cutaneous inflammation.9 The cutaneous flare response can be inhibited by prior treatment of the skin with topical capsaicin over several days. After such treatment, sensory nerves will be depleted of neuropeptides. After their release, neuropeptides act on target cells via a paracrine, juxtacrine, or endocrine pathway resulting in erythema, edema, hyperthermia, and pruritus. Because of their anatomic association with cutaneous nerves, mast cells and their released products appear to play an important role in mediating neuronal antidromic responses in the skin, although the precise role of these cells in cutaneous inflammation remains to be determined.
In contrast, afferent nerves express specific receptors for neuropeptides, prostaglandins, histamine, neurotrophins, proteases, vanilloids, and cytokines. This would indicate that an interactive communication network between sensory nerves and immune cells likely exists during cutaneous inflammation.
Finally, most cells expressing receptors for neuropeptides also generate neuropeptide-degrading peptidases such as neutral endopeptidase (NEP) or angiotensin-converting enzyme (ACE), thereby terminating the inflammatory stimulus by neuropeptides. Similarly, cells synthesizing receptors for the neurotransmitters acetylcholine and noradrenaline also generate enzymes that control the effects of these molecules. Thus, a close interaction between neuromediators, target cell receptors, and neuropeptide-degrading enzymes is critical for controlling cutaneous neurogenic inflammation.
NEUROPEPTIDES
Neuropeptides are a group of small peptides with 4 to more than 40 amino acids. More than 20 neuropeptides have been identified and more or less characterized in the skin of various species. However, regarding the function of a neuropeptide, organ- and species-specific effects must be considered in the interpretation of the observed effects. The most recognized neuropeptides in the skin are substance P (SP), neurokinin (NK) A, neurotensin, CGRP, VIP, pituitary adenylate cyclase activating polypeptide (PACAP), neuropeptide Y, somatostatin (SOM),  -endorphin, enkephalin, galanin, dynorphin, atrial natriuretic peptide,  - or  -melanocyte-stimulating hormone (MSH), parathyroid hormone–related protein, corticotropin-releasing hormone, and urocortin (Table 1). Under physiologic circumstances, cutaneous cells such as keratinocytes, microvascular endothelial cells, Merkel cells, fibroblasts, and leukocytes are also capable of releasing neuropeptides. Herein, we report our findings on some of these neuropeptides, while others are elucidated elsewhere.7-8,10-15
|
|
|
|
Neuromediators in the Skin
|
|
|
Tachykinins
Tachykinins are small peptides consisting of 10 to 13 amino acids. In the skin, SP effects have been described on keratinocytes including hair follicles, mast cells, fibroblasts, and endothelial cells. Increased epidermal SP-immunoreactive nerve fibers have been observed in certain inflammatory human skin diseases.16 The expression of tachykinins can be regulated by proinflammatory mediators (interleukin [IL] 1 and lipopolysaccharide) and neurotrophins (nerve growth factor [NGF]).17-18
Release of SP induces vascular responses and pruritus. For example, SP stimulates release of tumor necrosis factor , histamine, prostaglandin D2, and leukotriene B4 from skin mast cells.19 Acute immobilization stress induces skin mast cell degranulation via SP, corticotropin-releasing hormone, and neurotensin release, which suggests that stress by activation of certain neuropeptides may trigger mast cell degranulation and thereby modulate cutaneous neurogenic inflammation and pruritus.20
Neuropeptides are also capable of activating human dermal microvascular endothelial cells in vivo and in vitro.21 Substance P induces up-regulation of cell adhesion molecules such as P-selectin, intercellular adhesion molecule (ICAM) 1, and vascular cell adhesion molecule (VCAM) 122; recruitment of neutrophils and eosinophils; and the release of chemokines such as IL-8. Together, these results suggest an important direct effect of SP for leukocyte-endothelial interactions in the skin.23
In keratinocytes, SP and NK-A stimulate production of the proinflammatory cytokines IL-1, IL-1, and IL-8 as well as the IL-1 receptor antagonist.24-25 Up-regulation of keratinocyte cell adhesion molecule expression (ICAM-1) can be also modulated by SP.26
In fibroblasts, SP promotes chemotaxis27 via activation of the neurokinin-1 receptor (NK-1R). By augmenting cytokine-induced fibroblast proliferation and VCAM-1 expression, SP may be involved in the pathophysiology of autoimmune diseases and fibrosis.28 Transcription factors such as nuclear transcription factor  B (NF-B), nuclear factor of activated T cells, and AP-1,29 which are crucially involved in inflammation, can be regulated via tachykinins.
Substance P, NK-A, and NK-B bind with different affinities to 3 potential neurokinin receptors. Keratinocytes, Langerhans cells, Merkel cells, fibroblasts, mast cells, and endothelial cells express functional neurokinin receptors, while G proteins of mast cells can be additionally activated by SP in a nonreceptor-mediated fashion.30 To date, 3 neurokinin receptors have been cloned and characterized that differ in their binding affinity to SP, NK-A, and NK-B. Expression of NK-2R is significantly higher in murine keratinocytes,25 while NK-1R is preferentially expressed on human keratinocytes.29 Whether dysregulation of receptor activation or termination (polymorphisms and/or signal transduction) actively contributes to cutaneous diseases is currently unknown. However, NK-1R gene–deficient mice do not show a specific skin-related phenotype under normal conditions but instead show characteristic signs of edema and plasma extravasation.31 No NK-1R–mediated effects were observed in an experimentally induced wound-healing model.32 Additionally, previous studies have demonstrated that neurokinin receptor antagonists may be beneficial substrates for the treatment of inflammatory skin diseases.33-35
VIP and PACAP
Vasoactive intestinal peptide is a 28–amino acid peptide detected in nerve fibers associated with dermal vessels, sweat, apocrine, and meibomian glands, hair follicles, and Merkel cells. Fibers staining for VIP can also be found in close anatomic connection to mast cells and sweat glands.36 In lesional skin of patients with psoriasis VIP was increased, whereas the concentration of this neuropeptide was diminished in atopic dermatitis.37 Accordingly, VIP directly inhibited experimentally induced contact dermatitis in humans.38-40
Vasoactive intestinal peptide mediates vasodilatation by inducing nitric oxide synthesis41 and keratinocyte proliferation and migration42; induces sweat production43; and may be an important transmitter during neurogenic inflammation possibly by inducing histamine release from mast cells.44 Similar to tachykinins, the distribution of the neuropeptide receptor subfamilies varies within the epidermal and dermal compartment. While VPAC-1R (vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide 1 receptor) appears to be the predominant receptor on human dermal microvascular endothelial cells, keratinocytes predominantly express VPAC-2R.45
Pituitary adenylate cyclase activating polypeptide is a novel member belonging to the VIP family. Two forms can be distinguished: PACAP-38 and a truncated product, PACAP-27.46 While PACAP has been localized in cutanous nerve fibers of rodents and humans where it is involved in sensory, nociceptive, and probably autonomic pathways,47 the highest immunoreactivity was found around blood vessels, hair follicles, and close to sweat glands.
Pituitary adenylate cyclase activating polypeptide modulates inflammatory responses in the skin: PACAP-27 produces a long-lasting depression of a C-fiber–evoked flexion reflex in rats, potentiates vasodilatation and edema, and mediates plasma extravasation in the skin.48-49 These effects may be indirectly mediated via mast cells.50 Recently, the distribution of PACAP-38 was described in human skin, although its role is still uncertain.51-52 Additionally, enhanced concentrations of PACAP-38 were measured in lesional skin of patients with psoriasis.52
Three different VIP/PACAP receptors (PAC-Rs) with additional splicing products have been cloned53 and defined as PAC-1R, VPAC-1R (or VIP-1R), and VPAC-2R (or VIP-2R). Since VIP and PACAP are capable of binding identical receptors in the same tissue but with different affinities, a differential fine-tuned interaction between these 2 peptides is suggested. The PACAP/VIP receptor family can be found in several species. In humans, all 3 receptor subtypes can be detected in different peripheral organs. Receptor VPAC-1R was detected in endothelial cells, VPAC-1R and VPAC-2R in smooth muscle cells, and VPAC-1R in keratinocytes.54-55
Recent observations indicate that PACAP and VPAC-Rs are involved in the modulation of immune cells. In T cells or macrophages, PACAP down-regulates IL-2 and IL-6 production and inhibits IL-10 expression.56 Vasoactive intestinal peptide and PACAP both inhibit the lipopolysaccharide-stimulated production of tumor necrosis factor via VPAC-1R.57-58 Recently, an anti-inflammatory role of both VIP and PACAP was demonstrated in the chronic inflammatory disease rheumatoid arthritis.59-60 Thus, PACAP may have a proinflammatory effect on endothelial cells during acute inflammation, yet it exerts anti-inflammatory effects under chronic inflammatoy conditions.
Calcitonin Gene-Related Peptide
Calcitonin gene-related peptide is one of the most prominent neuropeptides of the skin and is often associated with mast cells, Merkel cells, melanocytes, keratinocytes, and Langerhans cells. It is capable of increasing keratinocyte proliferation61 and regulating cytokine production in human keratinocytes, and it exerts its effects predominantly on arterioles, resulting in vasodilatation.62 In general, CGRP predominantly mediates anti-inflammatory and neurotrophic effects.63 Under certain circumstances, CGRP enhanced the accumulation of neutrophils and edema formation induced by IL-1.64-65
Calcitonin gene-related peptide receptors can be subdivided into 2 classes: CGRP-1 and CGRP-2. Both receptor subtypes can be differentiated by their pharmacologic characteristics. Recently, the calcitonin gene–like receptor was localized in human skin.66 Additionally, a family of CGRP receptor activity–modifying proteins have been identified in humans.67 The fact that these proteins are differently regulated during different disease states indicates a regulatory role for them and calcitonin gene-related–like receptors in tissue pathophysiology.68
POMC-Derived Peptides
Pro-opiomelanocortin (POMC) peptides are expressed by melanocytes, keratinocytes, microvascular endothelial cells, Langerhans cells, mast cells, and fibroblasts as well as by immune cells such as monocytes and macrophages. The POMC gene includes several bioactive peptides such as adrenocorticotrophic hormone, -lipotropin, -, -, and -MSH, and -endorphin. After cleavage by prohormone convertase 1 and 2, a POMC prohormone generates up to 8 different POMC peptides. These enzymes appear to be crucial for the tissue specificity of POMC-derived peptides.
Several studies have demonstrated a direct immunoregulatory and anti-inflammatory role of -MSH in the skin in vivo and cutaneous cells in vitro. For example, -MSH antagonizes the effects of proinflammatory cytokines such as IL-1, IL-1, IL-6, and tumor necrosis factor or endotoxins69-70 and down-regulates the production of proinflammatory cytokines and accessory molecules on antigen-presenting cells, while production of suppressor factors such as IL-10 is up-regulated by -MSH.71
-Melanocyte-stimulating hormone up-regulates the expression of matrix metalloproteinase 172 and induces IL-8 release in cultured fibroblasts,73 which indicates a role of this neuropetide during dermal inflammatory processes. Moreover, fibroblast-derived -endorphin induces histamine release, which demonstrates a possible interaction of fibroblasts and mast cells via POMC peptides.74
Inflammatory mediators such as UV light or IL-1 up-regulate POMC messenger RNA in dermal endothelial cells.75 Melanocortin 1 receptor (MC-1R) expression was also increased in these cells on stimulation with IL-1. -Melanocyte-stimulating hormone induces increased levels of the chemokines IL-8 and Gro- (growth-related oncogene-) in human dermal microvascular endothelial cells via MC-1R.69 Some of the anti-inflammatory properties of -MSH appear to be mediated by down-regulating NF-B.76-78
Proopiomelanocortin peptides exert their effects via 5 subtypes of heterodimeric G protein–coupled melanocortin receptors (MC-1R–MC-5R) with 7 transmembrane domains: endothelial cells, fibroblasts, keratinocytes, monocytes, and melanocytes express MC-1R, while MC-2R and MC-5R are synthesized in muscle cells and adipocytes.79
CLASSIC NEUROTRANSMITTERS
Acetylcholine, epinephrine, and norepinephrine are small nonpeptide messengers produced by neurons and non-neuronal cells of various tissues including the skin.7 Originally, these molecules were described as important mediators released from autonomic nerve fibers. Recent studies suggest that adrenergic and cholinergic transmitters play important roles in cutaneous homeostasis and inflammation.3, 6 For example, catecholamines down-regulate the capability of antigen presentation in murine Langerhans cells via activation of 2 adrenergic receptors on these cells.4 Epinephrine also inhibits the induction of contact hypersensitivity to epicutaneously administered haptens in vivo, which dindicates a direct role of autonomic nerves in cutaneous immunomodulation.
Neurotrophins in the Skin
The mammalian skin expresses a variety of neurotrophic growth factors that are essential for growth, proliferation, and maintenance of nerves such as NGF, brain-derived NGF, neurotrophin-3, and neurotrophin-4/5. Cutaneous neurotrophins are expressed by sensory and sympathetic neurons and non-neuronal cells thereby regulating various biological modalities such as nociception, proprioception, mechanoreception, nerve growth and development, apoptosis, epidermal homeostasis, inflammation, hair growth, and melanogenesis.80 Several observations suggest that neurotrophins participate in the neuroimmunologic network, eg, expression of NGF and neurotrophins 3, 4, and 5 can be induced by cytokines such as IL-6 and soluble IL-6 receptor.81
During inflammation, NGF is markedly up-regulated in nerves associated with the inflamed area,82 and NGF levels are increased in inflammatory skin diseases such as psoriasis.83 Nerve growth factor also directly stimulates degranulation of mast cells, increases the number of mast cells, modulates B-cell function, and enhances histamine release from basophils. It is also capable of suppressing leukotriene C4 production in human eosinophils.84
Role of Transient Receptor Potentials in Cutaneous Inflammation
Clinically, topically applied capsaicin, a vanillyl-alkaloid found in red hot chili peppers, elicits a rapid sensation of burning pain by selectively activating small-diameter sensory neurons and triggering neurogenic inflammation.15 Long-term application of capsaicin leads to neurotoxic effects in sensory nerves and causes the termination of the inflammatory response, an effect that is used in the treatment of chronic inflammatory diseases.
Transient receptor potentials (TRPs) are a novel family of temperature-sensitive receptors with 6 transmembrane domains. These are nonselective cation channels that are structurally related to other members of store-operated calcium channels. Caterina et al85 recently described the successful molecular cloning of the rat capsaicin receptor (TRP vanilloid receptor 1 [TRP-V1]). Low pH levels that accompany inflammatory responses can increase the response of TRP-V1 to noxious stimuli, which suggests that the response of sensory nerve fibers during neurogenic inflammation results, at least in part, from activation of vanilloid receptors through an excess of protons, endogenous cannabinoids, and probably bradykinin.86 Recent data support a role of TRP-V1 in neurogenic inflammation.87 However, the role of TRP-Vs in cutaneous neurogenic inflammation is still unclear.
Role of Proteinase-Activated Receptors in Cutaneous Neurogenic Inflammation
Recent data strongly indicate that serine proteinases such as thrombin, cathepsin G, tryptase, and trypsin are not merely enzymes that degrade proteins and peptides in the extracellular space; they are also capable of mediating important effects during inflammation and immune response such as cytokine release, cell migration, recruitment of leukocytes, and endothelial cell activation.88-89 These processes are at least in part mediated by cleavage and activation of proteinase-activated receptors (PARs), which are G protein–coupled receptors with 7 transmembrane domains activated by proteolytic cleavage. So far, 4 PARs have been cloned and characterized.90 Activation of PARs results in the activation of signal transduction pathways ultimately involved in inflammatory signalling such as NF-B, mitogen-activated protein kinases, and protein kinase C.
Recent data suggest that PAR-1 and PAR-2 are involved in neurogenic inflammation,91-92 indicating that proteinases may activate PARs on sensory neurons to stimulate release of CGRP and SP, which mediate the inflammatory response. This is supported by several findings that natural and synthetic PAR agonists often mimic inflammatory effects of neuropeptides.93 For example, tryptase also induces plasma extravasation94 and neutrophil infiltration89, 91 and stimulates cytokine secretion.95 Tryptase-releasing mast cells can be found in close proximity to PAR-2–expressing cells such as keratinocytes and dermal endothelial cells96 or C-fibers during inflammation97-98 (Figure 1). Recent studies using PAR-2–deficient mice demonstrate that PAR-2 plays an important role in cutaneous inflammation in vivo, probably by stimulating nitric oxide release.91, 99 This is supported by findings in human skin tissues showing that PAR-2 agonists modulate plasma extravasation, edema, leukocyte recruitment, up-regulation of cell adhesion molecules on dermal microvascular endothelial cells, and pruritus.91, 99-100 Addtionally, PAR-2 is an inducer of the transcription factor NF-B, a factor that has been implicated in the pathophysiology of atopic dermatitis.101-102
MECHANISMS TO CONTROL NEUROGENIC INFLAMMATION
The physiologic control of cell responses to various inflammatory stimuli requires regulation at several levels. Stimulation of mast cells, for example, by SP results in modification of cell function at the transcriptional and post-transcriptional level such as cytokine synthesis or secretion. Receptor regulation is another point in the process at which to control cell function. On the receptor level, a variety of factors regulate receptor-ligand interactions such as receptor number, receptor affinity, receptor desensitization, uncoupling of receptors from its ligands, endocytosis, receptor recycling, and lysosomal trafficking. Moreover, signal amplification may occur through activation of specific second-messenger pathways. Thus, dysregulation of these processes may result in disease or uncontrolled inflammation. For example, degradation or abnormalities in the release of neuropeptides in receptor regulation or during signal transduction may result in neurogenic inflammation, vascular permeability, hyperalgesia, analgesia, or pruritus.
AGONIST REMOVAL BY NEUROPEPTIDE-DEGRADING ENZYMES
Recent studies indicate that NEP and ACE play an important role in the control of neurogenic inflammation. While ACE is capable of degrading the tachykinin SP, bradykinin, and angiotensin, NEP additionally cleaves NK-A, NK-B, VIP, PACAP, atrial natriuretic peptide, and endothelins. Both NEP and ACE have been identified in vascular endothelial cells,103 skin fibroblasts104 and keratinocytes.105-106 Additionally, ACE is predominantly found on the luminal side of vascular endothelium, which limits its range of actions predominantly to vascular responses (vasodilatation, plasma extravasation, and leukocyte-endothelium adhesion107).
In vivo studies using NEP-/-mice demonstrated a significant increase of plasma extravasation and cutaneous inflammation. The maximum was reached after 6 hours in a model of experimentally induced contact dermatitis,103 which indicates an anti-inflammatory role of NEP during cutaneous inflammation.
Neurokinin 1 receptor and NEP are often coexpressed by the same target cell. Thus, NEP can efficiently inhibit NK-1R signaling if expressed in high concentrations and in the vicinity of NK-1R at the cell surface.108 Neutral endopeptidase activity was found to be increased after stimulation with proinflammatory cytokines109 and glucocorticoids that also down-regulated NK-1R expression.110-111 Moreover, NEP is up-regulated during wound healing. Similar effects on cutaneous inflammation (contact hypersensitivity) were observed for ACE.112-113 These findings imply that up-regulation of NEP is a potential therapeutic approach to limiting the proinflammatory effects of neurogenic inflammation. Down-regulation of NEP and ACE may result in an uncontrolled stimulation of neuropeptides and lead to chronic inflammation.
CLINICAL IMPLICATIONS OF NEUROGENIC INFLAMMATION IN SKIN DISEASES
There is evidence that peripheral nerves contribute to the pathophysiology of urticaria, psoriasis, atopic dermatitis, hypersensitivity reactions, rosacea, and wound healing. Moreover, several of the neuromediators discussed herein are involved in the pathophysiology of pruritus as well as immunmodulation. Certain neuropeptides have been found to be enhanced in urticaria (SP, CGRP) or psoriasis (SP, PACAP). In addition, anti-inflammatory neuropeptides such as -MSH, VIP, and PACAP may be released to terminate inflammation under physiologic conditions. Thus, neuromediators are not necessarily proinflammatory but participate in all phases of the inflammatory response (acute, subacute, and chronic). For example, deficiency of PACAP and VIP had deleterious effects on the development of arthritis in a mouse model in vivo.
In patients with psoriasis, a significant reduction in the number of SOM- and factor XIIIa–positive dendritic cells were observed during topical treatment with clobetasol propionate or calcipotriol. Moreover, the efficiency of SOM or SOM analogues for the treatment of psoriasis and the observed reduction of SOM-positive cells during treatment support the idea that SOM might play a role during the clearing process of psoriasis.114
Recent evidence also suggests a role of NGF as a mediator of inflammatory responses during psoriasis.115 Also, protease inhibitors and PAR-modulating agents have been discussed as potential therapeutic molecules for the treatment of allegic, atopic, and inflammatory diseases.91, 116
Pharmacologic targets for the development of new agents will include the neuropeptides released in the skin, neuropeptide receptors expressed on target cells in the skin, proteases that degrade neuropeptides, agents that modify the function of vanilloid receptors, and growth factors that influence cutaneous innervation. Similar to capsaicin, topical calcineurin inhibitors such as pimecrolimus significantly inhibited histamine release from skin mast cells, which indicates a beneficial role of novel topical immunosuppressants also during neurogenic inflammation.117 Whether these drugs also modulate the signalling of cytokines to nerves remains to be clarified.
In summary, the interaction of the skin with the peripheral as well as central nervous system plays a crucial role in skin homeostasis and disease states (Table 1). Recent discoveries about molecular mechanisms of neuropeptide and neuropeptide receptor functions along with the development of modern techniques offer exciting insights into a complex network of the skin, the nerves, and the immune system during inflammation. Using novel technical approaches, physicians may define new ways to treat inflammatory skin diseases involving the neuro-immuno-endocrine axis.
AUTHOR INFORMATION
Corresponding author and reprints: Martin Steinhoff, MD, PhD, Department of Dermatology, University of Münster, von-Esmarch-Str 58, 48129 Münster, Germany (e-mail: msteinho{at}uni-muenster.de).
Accepted for publication August 28, 2003.
This study was supported by grants IZKF, Fö.01KS9604/0, DFG STE 1014, and SFB 293 from the Federal Ministry of Education and Research, Münster, Germany (Dr Steinhoff); Centre de Recherches et d' Investigations Epidermiques et Sensorielles, Paris, France; and Boltzmann Institute, Münster, Germany (Drs Luger and Steinhoff).
From the Departments of Dermatology (Drs Steinhoff, Ständer, and Luger) and Pediatrics, University of Muenster, Muenster (Dr Seeliger); Anesthesiology and Intensive Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Heidelberg (Dr Schmelz), Germany; and Dermatology, Western University, Chicago, Ill (Dr Ansel).
REFERENCES
1. Brain SD, Williams TJ. Inflammatory oedema induced by synergism between calcitonin gene-related peptide (CGRP) and mediators of increased vascular permeability. Br J Pharmacol. 1985;86:855-860.
ISI
| PUBMED
2. Wallengren J, Badendick K, Sundler F, Hakanson R, Zander E. Innervation of the skin of the forearm in diabetic patients. Acta Derm Venereol. 1995;75:37-42.
ISI
| PUBMED
3. Grando SA. Biological functions of keratinocyte cholinergic receptors. J Investig Dermatol Symp Proc. 1997;2:41-48.
PUBMED
4. Seiffert K, Hosoi J, Torii H, et al. Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol. 2002;168:6128-6135.
FREE FULL TEXT
5. Paus R, Peters EM, Eichmuller S, Botchkarev VA. Neural mechanisms of hair growth control. J Investig Dermatol Symp Proc. 1997;2:61-68.
PUBMED
6. Schallreuter KU. Epidermal adrenergic signal transduction as part of the neuronal network in the human epidermis. J Investig Dermatol Symp Proc. 1997;2:37-40.
PUBMED
7. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev. 2000;21:457-487.
FREE FULL TEXT
8. Seiffert K, Granstein RD. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods. 2002;28:97-103.
FULL TEXT
|
ISI
| PUBMED
9. Szolcsanyi J. Capsaicin-sensitive sensory nerve terminals with local and systemic efferent functions. Prog Brain Res. 1996;113:343-359.
ISI
| PUBMED
10. Legat FJ, Armstrong CA, Ansel JC. The cutaneous neurosensory system in skin disease. Adv Dermatol. 2002;18:91-109.
PUBMED
11. Ansel JC, Armstrong CA, Song I, et al. Interactions of the skin and nervous system. J Investig Dermatol Symp Proc. 1997;2:23-26.
PUBMED
12. Slominski A, Wortsman J, Pisarchik A, et al. Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001;15:1678-1693.
FREE FULL TEXT
13. Misery L. Langerhans cells in the neuro-immuno-cutaneous system. J Neuroimmunol. 1998;89:83-87.
FULL TEXT
|
ISI
| PUBMED
14. Luger TA. Neuromediators: a crucial component of the skin immune system. J Dermatol Sci. 2002;30:87-93.
FULL TEXT
|
ISI
| PUBMED
15. Steinhoff M, Ständer S, Luger TA. Regulatory mechanisms of neuroimmunology of the skin. In: Bienenstock J, Goetzl EJ, eds. Biology of the Autonomic Nervous System. New York, NY: Marcel Dekker Inc; 2002:279-298.
16. Misery L. Skin, immunity and the nervous system. Br J Dermatol. 1997;137:843-850.
FULL TEXT
|
ISI
| PUBMED
17. Freidin M, Kessler JA. Cytokine regulation of substance P expression in sympathetic neurons. Proc Natl Acad Sci U S A. 1991;88:3200-3203.
FREE FULL TEXT
18. Bost KL, Breeding SA, Pascual DW. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Reg Immunol. 1992;4:105-112.
PUBMED
19. Furutani K, Koro O, Hide M, Yamamoto S. Substance P- and antigen-induced release of leukotriene B4, prostaglandin D2 and histamine from guinea pig skin by different mechanisms in vitro. Arch Dermatol Res. 1999;291:466-473.
FULL TEXT
|
ISI
| PUBMED
20. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology. 1998;139:403-413.
FREE FULL TEXT
21. Wiedermann CJ, Auer B, Sitte B, et al. Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol. 1996;298:335-338.
FULL TEXT
|
ISI
| PUBMED
22. Quinlan KL, Song IS, Naik SM, et al. VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol. 1999;162:1656-1661.
FREE FULL TEXT
23. Pinter E, Than M, Chu DQ, Fogg C, Brain SD. Interaction between interleukin 1 and endogenous neurokinin 1 receptor agonists in mediating plasma extravasation and neutrophil accumulation in the cutaneous microvasculature of the rat. Neurosci Lett. 2002;318:13-16.
FULL TEXT
|
ISI
| PUBMED
24. McGovern UB, Jones KT, Sharpe GR. Intracellular calcium as a second messenger following growth stimulation of human keratinocytes. Br J Dermatol. 1995;132:892-896.
ISI
| PUBMED
25. Song IS, Bunnett NW, Olerud JE, et al. Substance P induction of murine keratinocyte PAM 212 interleukin 1 production is mediated by the neurokinin 2 receptor (NK-2R). Exp Dermatol. 2000;9:42-52.
FULL TEXT
|
ISI
| PUBMED
26. Viac J, Gueniche A, Doutremepuich JD, Reichert U, Claudy A, Schmitt D. Substance P and keratinocyte activation markers: an in vitro approach. Arch Dermatol Res. 1996;288:85-90.
FULL TEXT
|
ISI
| PUBMED
27. Kahler CM, Sitte BA, Reinisch N, Wiedermann CJ. Stimulation of the chemotactic migration of human fibroblasts by substance P. Eur J Pharmacol. 1993;249:281-286.
FULL TEXT
|
ISI
| PUBMED
28. Katayama I, Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation. J Dermatol Sci. 1997;15:201-206.
FULL TEXT
|
ISI
| PUBMED
29. Quinlan KL, Naik SM, Cannon G, et al. Substance P activates coincident NF-AT- and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol. 1999;163:5656-5665.
FREE FULL TEXT
30. Staniek V, Misery L, Peguet-Navarro J, et al. Binding and in vitro modulation of human epidermal Langerhans cell functions by substance P. Arch Dermatol Res. 1997;289:285-291.
FULL TEXT
|
ISI
| PUBMED
31. Cao T, Pinter E, Al-Rashed S, Gerard N, Hoult JR, Brain SD. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature. J Immunol. 2000;164:5424-5429.
FREE FULL TEXT
32. Cao T, Grant AD, Gerard NP, Brain SD. Lack of a significant effect of deletion of the tachykinin neurokinin-1 receptor on wound healing in mouse skin. Neuroscience. 2001;108:695-700.
FULL TEXT
|
ISI
| PUBMED
33. Palframan RT, Costa SK, Wilsoncroft P, Antunes E, de Nucci G, Brain SD. The effect of a tachykinin NK1 receptor antagonist, SR140333, on oedema formation induced in rat skin by venom from the Phoneutria nigriventer spider. Br J Pharmacol. 1996;118:295-298.
ISI
| PUBMED
34. Habler HJ, Timmermann L, Stegmann JU, Janig W. Involvement of neurokinins in antidromic vasodilatation in hairy and hairless skin of the rat hindlimb. Neuroscience. 1999;89:1259-1268.
FULL TEXT
|
ISI
| PUBMED
35. Lofgren O, Qi Y, Lundeberg T. Inhibitory effects of tachykinin receptor antagonists on thermally induced inflammatory reactions in a rat model. Burns. 1999;25:125-129.
FULL TEXT
|
ISI
| PUBMED
36. Harvima IT, Viinamaki H, Naukkarinen A, et al. Association of cutaneous mast cells and sensory nerves with psychic stress in psoriasis. Psychother Psychosom. 1993;60:168-176.
FULL TEXT
|
ISI
| PUBMED
37. Eedy DJ, Johnston CF, Shaw C, Buchanan KD. Neuropeptides in psoriasis. J Invest Dermatol. 1991;96:434-438.
FULL TEXT
|
ISI
| PUBMED
38. Lundeberg L, Nordlind K. Vasoactive intestinal polypeptide in allergic contact dermatitis: an immunohistochemical and radioimmunoassay study. Arch Dermatol Res. 1999;291:201-206.
FULL TEXT
|
ISI
| PUBMED
39. Lundeberg L, Mutt V, Nordlind K. Inhibitory effect of vasoactive intestinal peptide on the challenge phase of allergic contact dermatitis in humans. Acta Derm Venereol. 1999;79:178-182.
FULL TEXT
|
ISI
| PUBMED
40. Bondesson L, Nordlind K, Mutt V, Liden S. Vasoactive intestinal polypeptide inhibits the established allergic contact dermatitis in humans. Ann N Y Acad Sci. 1996;805:702-707.
ISI
| PUBMED
41. Williams TJ. Vasoactive intestinal polypeptide is more potent than prostaglandin E2 as a vasodilator and oedema potentiator in rabbit skin. Br J Pharmacol. 1982;77:505-509.
ISI
| PUBMED
42. Wollina U, Huschenbeck J, Knoll B, Sternberg B, Hipler UC. Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix. Regul Pept. 1997;70:29-36.
FULL TEXT
|
ISI
| PUBMED
43. Sato K, Sato F. Effect of VIP on sweat secretion and cAMP accumulation in isolated simian eccrine glands. Am J Physiol. 1987;253:R935-R941.
FREE FULL TEXT
44. Warren JB, Wilson AJ, Loi RK, Coughlan ML. Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J. 1993;7:1394-1400.
ABSTRACT
45. Fischer TC, Dinh QT, Peiser C, Loser C, Fischer A, Groneberg DA. Simultaneous detection of receptor mRNA and ligand protein in human skin tissues. J Cutan Pathol. 2002;29:65-71.
FULL TEXT
|
ISI
| PUBMED
46. Hosoya M, Onda H, Ogi K, et al. Molecular cloning and functional expression of rat cDNAs encoding the receptor for pituitary adenylate cyclase activating polypeptide (PACAP). Biochem Biophys Res Commun. 1993;194:133-143.
FULL TEXT
|
ISI
| PUBMED
47. Dun EC, Huang RL, Dun SL, Dun NJ. Pituitary adenylate cyclase activating polypeptide-immunoreactivity in human spinal cord and dorsal root ganglia. Brain Res. 1996;721:233-237.
FULL TEXT
|
ISI
| PUBMED
48. Warren JB, Larkin SW, Coughlan M, Kajekar R, Williams TJ. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator and oedema potentiator in rabbit skin in vivo. Br J Pharmacol. 1992;106:331-334.
ISI
| PUBMED
49. Cardell LO, Stjarne P, Wagstaff SJ, Agusti C, Nadel JA. PACAP-induced plasma extravasation in rat skin. Regul Pept. 1997;71:67-71.
FULL TEXT
|
ISI
| PUBMED
50. Schmidt-Choudhury A, Meissner J, Seebeck J, et al. Stem cell factor influences neuro-immune interactions. Regul Pept. 1999;83:73-80.
FULL TEXT
|
ISI
| PUBMED
51. Odum L, Petersen LJ, Skov PS, Ebskov LB. Pituitary adenylate cyclase activating polypeptide (PACAP) is localized in human dermal neurons and causes histamine release from skin mast cells. Inflamm Res. 1998;47:488-492.
FULL TEXT
|
ISI
| PUBMED
52. Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin. Regul Pept. 1999;80:49-55.
FULL TEXT
|
ISI
| PUBMED
53. Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors. Front Neuroendocrinol. 1995;16:53-88.
FULL TEXT
|
ISI
| PUBMED
54. Granothab R, Fridkinb M, Gozesa I. VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes. FEBS Lett. 2000;475:78-83.
FULL TEXT
|
ISI
| PUBMED
55. Sung KJ, Chang SE, Paik EM, Lee MW, Choi JH. Vasoactive intestinal polypeptide stimulates the proliferation of HaCaT cell via TGF-alpha. Neuropeptides. 1999;33:435-446.
FULL TEXT
|
ISI
| PUBMED
56. Martinez C, Delgado M, Pozo D, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol. 1998;63:591-601.
ABSTRACT
57. Delgado M, Pozo D, Martinez C, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages. J Immunol. 1999;162:2358-2367.
FREE FULL TEXT
58. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162:1200-1205.
FREE FULL TEXT
59. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7:563-568.
FULL TEXT
|
ISI
| PUBMED
60. Abad C, Martinez C, Leceta J, Gomariz RP, Delgado M. Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy. J Immunol. 2001;167:3182-3189.
FREE FULL TEXT
61. Hara M, Toyoda M, Yaar M, et al. Innervation of melanocytes in human skin. J Exp Med. 1996;184:1385-1395.
FREE FULL TEXT
62. Brain SD, Williams TJ. Interactions between the tachykinins and calcitonin gene-related peptide lead to the modulation of oedema formation and blood flow in rat skin. Br J Pharmacol. 1989;97:77-82.
ISI
| PUBMED
63. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996;17:533-585.
FREE FULL TEXT
64. Sung CP, Arleth AJ, Aiyar N, Bhatnagar PK, Lysko PG, Feuerstein G. CGRP stimulates the adhesion of leukocytes to vascular endothelial cells. Peptides. 1992;13:429-434.
FULL TEXT
|
ISI
| PUBMED
65. Buckley TL, Brain SD, Jose PJ, Williams TJ. The partial inhibition of inflammatory responses induced by capsaicin using the Fab fragment of a selective calcitonin gene-related peptide antiserum in rabbit skin. Neuroscience. 1992;48:963-968.
FULL TEXT
|
ISI
| PUBMED
66. Hagner S, Haberberger RV, Overkamp D, Hoffmann R, Voigt KH, McGregor GP. Expression and distribution of calcitonin receptor-like receptor in human hairy skin. Peptides. 2002;23:109-116.
FULL TEXT
|
ISI
| PUBMED
67. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998;393:333-339.
FULL TEXT
| PUBMED
68. Nagae T, Mukoyama M, Sugawara A, et al. Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and up-regulation in obstructive nephropathy. Biochem Biophys Res Commun. 2000;270:89-93.
FULL TEXT
|
ISI
| PUBMED
69. Hartmeyer M, Scholzen T, Becher E, Bhardwaj RS, Schwarz T, Luger TA. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J Immunol. 1997;159:1930-1937.
ABSTRACT
70. Bohm M, Luger TA. The pilosebaceous unit is part of the skin immune system. Dermatology. 1998;196:75-79.
FULL TEXT
|
ISI
| PUBMED
71. Grabbe S, Bhardwaj RS, Mahnke K, Simon MM, Schwarz T, Luger TA. alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J Immunol. 1996;156:473-478.
ABSTRACT
72. Kiss M, Wlaschek M, Brenneisen P, et al. Alpha-melanocyte stimulating hormone induces collagenase/matrix metalloproteinase-1 in human dermal fibroblasts. Biol Chem Hoppe Seyler. 1995;376:425-430.
ISI
| PUBMED
73. Kiss M, Kemeny L, Gyulai R, et al. Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts. Inflammation. 1999;23:557-567.
FULL TEXT
|
ISI
| PUBMED
74. Teofoli P, Frezzolini A, Puddu P, De Pita O, Mauviel A, Lotti T. The role of proopiomelanocortin-derived peptides in skin fibroblast and mast cell functions. Ann N Y Acad Sci. 1999;885:268-276.
ISI
| PUBMED
75. Scholzen TE, Kalden D, Brzoska T, et al. Expression of proopiomelanocortin peptides in human dermal microvascular endothelial cells: evidence for a regulation by ultraviolet light and interleukin-1. J Invest Dermatol. 2000;115:1021-1028.
FULL TEXT
|
ISI
| PUBMED
76. Kalden DH, Scholzen T, Brzoska T, Luger TA. Mechanisms of the anti-inflammatory effects of alpha-MSH: role of transcription factor NF-kappa B and adhesion molecule expression. Ann N Y Acad Sci. 1999;885:254-261.
ISI
| PUBMED
77. Ichiyama T, Okada K, Campbell IL, Furukawa S, Lipton JM. NF-kappaB activation is inhibited in human pulmonary epithelial cells transfected with alpha-melanocyte-stimulating hormone vector. Peptides. 2000;21:1473-1477.
FULL TEXT
|
ISI
| PUBMED
78. Haycock JW, Wagner M, Morandini R, Ghanem G, Rennie IG, MacNeil S. Alpha-MSH immunomodulation acts via rel/NF-kappa B in cutaneous and ocular melanocytes and in melanoma cells. Ann N Y Acad Sci. 1999;885:396-399.
ISI
| PUBMED
79. Bohm M, Schulte U, Goez R, Luger TA. Human dermal fibroblasts express melanocortin-1 receptors and respond to a-melanocyte stimulating hormone with increased secretion of IL-8 [abstract]. Arch Dermatol Res. 1998;290:104.
80. Bergman E, Ulfhake B, Fundin BT. Regulation of NGF-family ligands and receptors in adulthood and senescence: correlation to degenerative and regenerative changes in cutaneous innervation. Eur J Neurosci. 2000;12:2694-2706.
FULL TEXT
|
ISI
| PUBMED
81. Marz P, Heese K, Dimitriades-Schmutz B, Rose-John S, Otten U. Role of interleukin-6 and soluble IL-6 receptor in region-specific induction of astrocytic differentiation and neurotrophin expression. Glia. 1999;26:191-200.
FULL TEXT
|
ISI
| PUBMED
82. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience. 1992;49:693-698.
FULL TEXT
|
ISI
| PUBMED
83. Fantini F, Magnoni C, Bracci-Laudiero L, Pincelli CT. Nerve growth factor is increased in psoriatic skin [letter]. J Invest Dermatol. 1995;105:854-855.
FULL TEXT
|
ISI
| PUBMED
84. Takafuji S, Bischoff SC, De Weck AL, Dahinden CA. Opposing effects of tumor necrosis factor-alpha and nerve growth factor upon leukotriene C4 production by human eosinophils triggered with N-formyl-methionyl-leucyl-phenylalanine. Eur J Immunol. 1992;22:969-974.
ISI
| PUBMED
85. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway [see comments]. Nature. 1997;389:816-824.
86. Carr MJ, Kollarik M, Meeker SN, Undem BJ. A role for TRPV1 in bradykinin-induced excitation of vagal airway afferent nerve terminals. J Pharmacol Exp Ther. 2003;304:1275-1279.
FREE FULL TEXT
87. Rigoni M, Trevisani M, Gazzieri D, et al. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin. Br J Pharmacol. 2003;138:977-985.
FULL TEXT
|
ISI
| PUBMED
88. Dery O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998;274:C1429-C1452.
89. Vergnolle N. Proteinase-activated receptor-2-activating peptides induce leukocyte rolling, adhesion, and extravasation in vivo. J Immunol. 1999;163:5064-5069.
FREE FULL TEXT
90. MacFarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
FREE FULL TEXT
91. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6:151-158.
FULL TEXT
|
ISI
| PUBMED
92. de Garavilla L, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol. 2001;133:975-987.
FULL TEXT
|
ISI
| PUBMED
93. Emilsson K, Wahlestedt C, Sun MK, Nystedt S, Owman S, Sundelin J. Vascular effects of proteinase-activated receptor 2 agonist peptide. J Vasc Res. 1997;34:267-272.
ISI
| PUBMED
94. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272:4043-4049.
FREE FULL TEXT
95. Hou L, Kapas S, Cruchley AT, et al. Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology. 1998;94:356-362.
FULL TEXT
|
ISI
| PUBMED
96. Hou L, Ravenall S, Macey MG, Harriott P, Kapas S, Howells GL. Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts. J Periodontal Res. 1998;33:205-211.
FULL TEXT
|
ISI
| PUBMED
97. Brain SD, Williams TJ. Neuropharmacology of peptides in skin. Semin Dermatol. 1988;7:278-283.
ISI
| PUBMED
98. Brain SD. Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology. 1997;37:133-152.
FULL TEXT
|
ISI
| PUBMED
99. Seeliger S, Derian C, Bunnett NW, et al. Proinflammatory role of proteinase-activated receptor-2 during cutaneous inflammation. FASEB J. In press.
100. Steinhoff M, Neisius U, Ikoma T, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23:6176-6180.
FREE FULL TEXT
101. Kanke T, MacFarlane SR, Seatter MJ, et al. Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes. J Biol Chem. 2001;276:31657-31666.
FREE FULL TEXT
102. Shpacovitch VM, Brzoska T, Buddenkotte J, et al. Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol. 2002;118:380-385.
FULL TEXT
|
ISI
| PUBMED
103. Scholzen T, Steinhoff M, Bonaccorsi P, et al. Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J Immunol. 2001;166:1285-1291.
FREE FULL TEXT
104. Johnson AR, Coalson JJ, Ashton J, Larumbide M, Erdos EG. Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome: comparison with angiotensin-converting enzyme. Am Rev Respir Dis. 1985;132:1262-1267.
ISI
| PUBMED
105. Muns G, Vishwanatha JK, Rubinstein I. Effects of smokeless tobacco on chemically transformed hamster oral keratinocytes: role of angiotensin I-converting enzyme. Carcinogenesis. 1994;15:1325-1327.
FREE FULL TEXT
106. Olerud JE, Usui ML, Seckin D, et al. Neutral endopeptidase expression and distribution in human skin and wounds. J Invest Dermatol. 1999;112:873-881.
FULL TEXT
|
ISI
| PUBMED
107. Caldwell PR, Seegal BC, Hsu KC, Das M, Soffer RL. Angiotensin-converting enzyme: vascular endothelial localization. Science. 1976;191:1050-1051.
FREE FULL TEXT
108. Okamoto A, Lovett M, Payan DG, Bunnett NW. Interactions between neutral endopeptidase (EC 3.4.24.11) and the substance P (NK1) receptor expressed in mammalian cells. Biochem J. 1994;299:683-693.
109. Kondepudi A, Johnson A. Cytokines increase neutral endopeptidase activity in lung fibroblasts. Am J Respir Cell Mol Biol. 1993;8:43-49.
110. Borson DB. Roles of neutral endopeptidase in airways. Am J Physiol. 1991;260:L212-L225.
FREE FULL TEXT
111. Borson DB, Gruenert DC. Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am J Physiol. 1991;260:L83-L89.
FREE FULL TEXT
112. Scholzen TE, Stander S, Riemann H, Brzoska T, Luger TA. Modulation of cutaneous inflammation by angiotensin-converting enzyme. J Immunol. 2003;170:3866-3873.
FREE FULL TEXT
113. Scholzen TE, Sunderkotter C, Kalden DH, et al. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology. 2003;144:360-370.
FREE FULL TEXT
114. Talme T, Schultzberg M, Sundqvist KG, Marcusson JA. Somatostatin- and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calciprotriol treatment. Acta Derm Venereol. 1999;79:44-48.
FULL TEXT
|
ISI
| PUBMED
115. Bull HA, Leslie TA, Chopra S, Dowd PM. Expression of nerve growth factor receptors in cutaneous inflammation [see comments]. Br J Dermatol. 1998;139:776-783.
FULL TEXT
|
ISI
| PUBMED
116. Brain SD. New feelings about the role of sensory nerves in inflammation [news]. Nat Med. 2000;6:134-135.
FULL TEXT
|
ISI
| PUBMED
117. Sabroe RA, Kennedy CT, Archer CB. The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br J Dermatol. 1997;137:386-390.
FULL TEXT
|
ISI
| PUBMED
118. Bering B, Moises HW, Muller WE. Muscarinic cholinergic receptors on intact human lymphocytes properties and subclass characterization. Biol Psychiatry. 1987;22:1451-1458.
FULL TEXT
|
ISI
| PUBMED
119. Iyengar B. Modulation of melanocytic activity by acetylcholine. Acta Anat (Basel). 1989;136:139-141.
ISI
| PUBMED
120. Grando SA, Crosby AM, Zelickson BD, Dahl MV. Agarose gel keratinocyte outgrowth system as a model of skin re-epithelization: requirement of endogenous acetylcholine for outgrowth initiation. J Invest Dermatol. 1993;101:804-810.
FULL TEXT
|
ISI
| PUBMED
121. Grando SA, Horton RM, Pereira EF, et al. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol. 1995;105:774-781.
FULL TEXT
|
ISI
| PUBMED
122. Grando SA, Zelickson BD, Kist DA, et al. Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization. J Invest Dermatol. 1995;104:95-100.
FULL TEXT
|
ISI
| PUBMED
123. Grando SA, Horton RM, Mauro TM, Kist DA, Lee TX, Dahl MV. Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol. 1996;107:412-418.
FULL TEXT
|
ISI
| PUBMED
124. Zia S, Ndoye A, Nguyen VT, Grando SA. Nicotine enhances expression of the alpha 3, alpha 4, alpha 5, and alpha 7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells. Res Commun Mol Pathol Pharmacol. 1997;97:243-262.
ISI
| PUBMED
125. Lammerding-Koppel M, Noda S, Blum A, Schaumburg-Lever G, Rassner G, Drews U. Immunohistochemical localization of muscarinic acetylcholine receptors in primary and metastatic malignant melanomas. J Cutan Pathol. 1997;24:137-144.
FULL TEXT
|
ISI
| PUBMED
126. Ndoye A, Buchli R, Greenberg B, et al. Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Dermatol. 1998;111:410-416.
FULL TEXT
|
ISI
| PUBMED
127. Schmelz M, Weber S, Kress M. Topical acetyl salicylate and dipyrone attenuate neurogenic protein extravasation in rat skin in vivo. Neurosci Lett. 2000;290:57-60.
FULL TEXT
|
ISI
| PUBMED
128. Rossi M, Cupisti A, Mariani S, Santoro G, Pentimone F. Endothelium-dependent and endothelium-independent skin vasoreactivity in the elderly. Aging Clin Exp Res. 2002;14:343-346.
ISI
| PUBMED
129. Arredondo J, Nguyen VT, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA. A receptor-mediated mechanism of nicotine toxicity in oral keratinocytes. Lab Invest. 2001;81:1653-1668.
ISI
| PUBMED
130. Berghoff M, Kathpal M, Kilo S, Hilz MJ, Freeman R. Vascular and neural mechanisms of ACh-mediated vasodilation in the forearm cutaneous microcirculation. J Appl Physiol. 2002;92:780-788.
FREE FULL TEXT
131. Kubli S, Boegli Y, Ave AD, et al. Endothelium-dependent vasodilation in the skin microcirculation of patients with septic shock. Shock. 2003;19:274-280.
ISI
| PUBMED
132. Katz DM, Markey KA, Goldstein M, Black IB. Expression of catecholaminergic characteristics by primary sensory neurons in the normal adult rat in vivo. Proc Natl Acad Sci U S A. 1983;80:3526-3530.
FREE FULL TEXT
133. Kaji A, Shigematsu H, Fujita K, Maeda T, Watanabe S. Parasympathetic innervation of cutaneous blood vessels by vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-positive nerves: histochemical and experimental study on rat lower lip. Neuroscience. 1988;25:353-362.
FULL TEXT
|
ISI
| PUBMED
134. Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature. 1986;323:158-160.
FULL TEXT
| PUBMED
135. Advenier C, Devillier P. Neurokinins and the skin. Allerg Immunol (Paris). 1993;25:280-282.
PUBMED
136. Schallreuter KU, Wood JM, Pittelkow MR, Swanson NN, Steinkraus V. Increased in vitro expression of beta 2-adrenoceptors in differentiating lesional keratinocytes of vitiligo patients. Arch Dermatol Res. 1993;285:216-220.
FULL TEXT
|
ISI
| PUBMED
137. Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta. 1994;1226:181-192.
PUBMED
138. Oya N, Suzuki Y, Tanemura M, et al. Detection of skin over cysts with spina bifida may be useful not only for preventing neurological damage during labor but also for predicting fetal prognosis. Fetal Diagn Ther. 2000;15:156-159.
FULL TEXT
|
ISI
| PUBMED
139. van der Voort R, Keehnen RM, Beulinng EA, Spaargaren M, Pals ST. Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans. J Exp Med. 2000;192:1115-1124.
FREE FULL TEXT
140. Ciioca DP, Watanabe N, Isobe M. Apoptosis of peripheral blood lymphocytes is induced by catecholamines. Jpn Heart J. 2000;41:385-398.
FULL TEXT
| PUBMED
141. Chen R, Fairley JA, Zhao ML, et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol. 2002;169:3987-3992.
FREE FULL TEXT
142. Michikami D, Iwase S, Kamiya A, Qi F, Mano T, Suzumura A. Interrelations of vasoconstrictor sympathetic outflow to skin core temperature during unilateral sole heating in humans. Auton Neurosci. 2001;91:55-61.
FULL TEXT
|
ISI
| PUBMED
143. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol. 1993;150:4478-4485.
ABSTRACT
144. Kramp RA, Genard J, Fourmanoir P, Caron N, Laekeman G, Herman A. Renal hemodynamics and blood flow autoregulation during acute cyclooxygenas inhibition in male rats. Am J Physiol. 1995;268:F468-F479.
FREE FULL TEXT
145. Columbo M, Horowitz EM, Kagey-Sobotka A, Lichtenstein LM. Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism. Clin Immunol Immunopathol. 1996;81:68-73.
FULL TEXT
|
ISI
| PUBMED
146. Wiedermann CJ, Auer B, Sitte B, Reinisch N, Schratzberger P, Kahler CM. Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol. 1996;298:335-358.
147. Quinlan KL, Song IS, Bunnett NW, et al. Neuropeptide regulation of human dermal microvascular endothelial cell ICAM-1 expression and function. Am J Physiol. 1998;275:C1580-C1590.
148. Smith GD, Seckl JR, Harmar AJ. Distribution of neuropeptides in dorsal root ganglia of the rat; substance P, somatostatin and calcitonin gene-related peptide. Neurosci Lett. 1993;153:5-8.
FULL TEXT
|
ISI
| PUBMED
149. Regoli D, Rizzi A, Calo G, Nsa Allogho S, Gobeil F. B1 and B2 kinin receptors in various species. Immunopharmacology. 1997;36:143-147.
FULL TEXT
|
ISI
| PUBMED
150. Okabe T, Hide M, Koro O, Yamamoto S. Substance P induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. Eur J Pharmacol. 2000;398:309-315.
FULL TEXT
|
ISI
| PUBMED
151. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147:71-79.
FULL TEXT
|
ISI
| PUBMED
152. Burbach GJ, Kim KH, Zivony AS. The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol. 2001;117:1075-1082.
FULL TEXT
|
ISI
| PUBMED
153. Tainio H. Cytochemical localization of VIP-stimulated adenylate cyclase activity in human sweat glands. Br J Dermatol. 1987;116:323-328.
FULL TEXT
|
ISI
| PUBMED
154. Schulze E, Witt M, Fink T, Hofer A, Funk RH. Immunohistochemical detection of human skin nerve fibers. Acta Histochem. 1997;99:301-309.
ISI
| PUBMED
155. Hartschuh W, Weihe E, Yanaihara N, Reinecke M. Immunohistochemical localization of vasoactive intestinal polypeptide (VIP) in Merkel cells of various mammals: evidence for a neuromodulator function of the Merkel cell. J Invest Dermatol. 1983;81:361-364.
FULL TEXT
|
ISI
| PUBMED
156. Naukkarinen A, Harvima I, Paukkonen K, Aalto ML, Horsmanheimo M. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res. 1993;285:341-346.
FULL TEXT
|
ISI
| PUBMED
157. Haegerstrand A, Jonzon B, Dalsgaard CJ, Nilsson J. Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989;86:5993-5996.
FREE FULL TEXT
158. Smith CH, Atkinson B, Morris RW, Hayes N, Foreman JC, Lee TH. Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria. Lancet. 1992;339:91-93.
FULL TEXT
|
ISI
| PUBMED
159. Gonzalez C, Barroso C, Martin C, Gulbenkian S, Estrada C. Neuronal nitric oxide synthase activation by vasoactive intestinal peptide in bovine cerebral arteries. J Cereb Blood Flow Metab. 1997;17:977-984.
FULL TEXT
|
ISI
| PUBMED
160. Eedy DJ, Shaw C, Johnston CF, Buchanan KD. The regional distribution of neuropeptides in human skin as assessed by radioimmunoassay and high-performance liquid chromatography. Clin Exp Dermatol. 1994;19:463-472.
FULL TEXT
|
ISI
| PUBMED
161. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000;52:269-324.
FREE FULL TEXT
162. Groneberg DA, Welker P, Fischer TC, et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol. 2003;111:1099-1105.
FULL TEXT
|
ISI
| PUBMED
163. Moller K, Zhang YZ, Hakanson R, et al. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience. 1993;57:725-732.
FULL TEXT
|
ISI
| PUBMED
164. Warren JB, Cockcroft JR, Larkin SW, et al. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol. 1992;20:83-87.
ISI
| PUBMED
165. Delgado M, Munoz-Elias EJ, Kan Y, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J Biol Chem. 1998;273:31427-31436.
FREE FULL TEXT
166. Delgado M, Ganea D. VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. Ann N Y Acad Sci. 2000;921:55-67.
FULL TEXT
|
ISI
| PUBMED
167. Schmidt-Choudhury A, Furuta GT, Galli SJ, Schmidt WE, Wershil BK. Mast cells contribute to PACAP-induced dermal oedema in mice. Regul Pept. 1999;82:65-69.
FULL TEXT
|
ISI
| PUBMED
168. Seebeck J, Kruse ML, Schmidt-Choudhury A, Schmidt WE. Pituitary adenylate cyclase activating polypeptide induces degranulation of rat peritoneal mast cells via high-affinity PACAP receptor-independent activation of GG proteins. Ann N Y Acad Sci. 1998;865:141-146.
FULL TEXT
|
ISI
| PUBMED
169. Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fournier A, Vaudry H. PACAP acts as a neurotrophic factor during histogenesis of the rat cerebellar cortex. Ann N Y Acad Sci. 2000;921:293-299.
FULL TEXT
|
ISI
| PUBMED
170. Sakashita Y, Kurihara T, Uchida D, Tatsuno I, Yamamoto T. Involvement of PACAP receptor in primary afferent fibre-evoked responses of ventral roots in the neonatal rat spinal cord. Br J Pharmacol. 2001;132:1769-1776.
FULL TEXT
|
ISI
| PUBMED
171. Haegerstrand A, Dalsgaard CJ, Jonzon B, Larsson O, Nilsson J. Calcitonin gene related peptide stimulates proliferation of human endothelial cells. Proc Natl Acad Sci U S A. 1990;87:3299-3303.
FREE FULL TEXT
172. Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003;295:2-7.
ISI
| PUBMED
173. Luger TA, Brzoska T, Scholzen TE, et al. The role of alpha-MSH as a modulator of cutaneous inflammation. Ann N Y Acad Sci. 2000;917:232-238.
ISI
| PUBMED
174. Grutzkau A, Henz BM, Kirchhof L, Luger T, Artuc M. alpha-Melanocyte stimulating hormone acts as a selective inducer of secretory functions in human mast cells. Biochem Biophys Res Commun. 2000;278:14-19.
FULL TEXT
|
ISI
| PUBMED
175. Catania A, Cutuli M, Garofalo L, et al. The neuropeptide alpha-MSH in host defense. Ann N Y Acad Sci. 2000;917:227-231.
ISI
| PUBMED
176. Adachi S, Nakano T, Vliagoftis H, Metcalfe DD. Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. J Immunol. 1999;163:3363-3368.
FREE FULL TEXT
177. Cone RD, Lu D, Koppula S, et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res. 1996;51:287-317.
178. Brzoska T, Kalden DH, Scholzen T, Luger TA. Molecular basis of the alpha-MSH/IL-1 antagonism. Ann N Y Acad Sci. 1999;885:230-238.
FULL TEXT
|
ISI
| PUBMED
179. Haycock JW, Rowe SJ, Cartledge S, et al. Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines. J Biol Chem. 2000;275:15629-15636.
FREE FULL TEXT
180. Funasaka Y, Chakraborty AK, Yodoi J, Ichihashi M. The effect of thioredoxin on the expression of proopiomelanocortin-derived peptides, the melanocortin 1 receptor and cell survival of normal human keratinocytes. J Investig Dermatol Symp Proc. 2001;6:32-37.
FULL TEXT
|
ISI
| PUBMED
181. Curry JL, Pinto W, Nickoloff BJ, Slominski AT. Human keratinocytes express functional alpha-MSH (MC1-R) receptors. In Vitro Cell Dev Biol Anim. 2001;37:234-236.
FULL TEXT
|
ISI
| PUBMED
182. Virador VM, Muller J, Wu X, et al. Influence of alpha-melanocyte-stimulating hormone and ultraviolet radiation on the transfer of melanosomes to keratinocytes. FASEB J. 2002;16:105-107.
FREE FULL TEXT
183. Moustafa M, Szabo M, Ghanem GE, et al. Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. J Invest Dermatol. 2002;119:1244-1253.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Neuronal Sensitization for Histamine-Induced Itch in Lesional Skin of Patients With Atopic Dermatitis
Akihiko Ikoma, Roman Rukwied, Sonja Ständer, Martin Steinhoff, Yoshiki Miyachi, and Martin Schmelz
Arch Dermatol. 2003;139(11):1455-1458.
ABSTRACT
| FULL TEXT
Neurophysiology of Pruritus: Cutaneous Elicitation of Itch
Sonja Ständer, Martin Steinhoff, Martin Schmelz, Elke Weisshaar, Dieter Metze, and Thomas Luger
Arch Dermatol. 2003;139(11):1463-1470.
ABSTRACT
| FULL TEXT
Neurophysiology of Pruritus: Interaction of Itch and Pain
Akihiko Ikoma, Roman Rukwied, Sonja Ständer, Martin Steinhoff, Yoshiki Miyachi, and Martin Schmelz
Arch Dermatol. 2003;139(11):1475-1478.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Altered Molecular Mechanisms of Diabetic Foot Ulcers
Blakytny and Jude
INT J LOW EXTREM WOUNDS 2009;8:95-104.
ABSTRACT
Mast Cell-Derived Tumor Necrosis Factor Can Promote Nerve Fiber Elongation in the Skin during Contact Hypersensitivity in Mice
Kakurai et al.
Am. J. Pathol. 2006;169:1713-1721.
ABSTRACT
| FULL TEXT
Nerve fibres in peritoneal endometriosis
Tokushige et al.
Hum Reprod 2006;21:3001-3007.
ABSTRACT
| FULL TEXT
Neuronal control of skin function: the skin as a neuroimmunoendocrine organ.
Roosterman et al.
Physiol. Rev. 2006;86:1309-1379.
ABSTRACT
| FULL TEXT
Increased Innervation and Ripening of the Prepartum Murine Cervix
Kirby et al.
Reproductive Sciences 2005;12:578-585.
ABSTRACT
Psoriasis
Schön and Boehncke
NEJM 2005;352:1899-1912.
FULL TEXT
Neurogenic Inflammation in Stress-Induced Termination of Murine Hair Growth Is Promoted by Nerve Growth Factor
Peters et al.
Am. J. Pathol. 2004;165:259-271.
ABSTRACT
| FULL TEXT
|
